Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

Conditions

• Antibiotic Resistance Genes
• Human Genome Analysis
• Infection Mixed
• Infection, Bacterial
• Infection, Coronavirus
• Infection, Fungal
• Sepsis
• Systemic Inflammatory Response Syndrome

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly) — DEVICE
  The Gene Z device (no longer in use) and now using In-Dx created in our lab, and other rapid diagnostic techniques that we have developed in our lab will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device or other rapid diagnostic techniques developed in our lab will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results

Study Details

The aim of this project is to test the utility of The Gene Z device (as of 2018 Gene Z no longer being used), now using In-Dx and other rapid identification techniques that the investigators have developed in the lab on clinically obtained bodily fluid samples taken from patients with suspected infection or sepsis based on having three of four positive Systemic Inflammatory Response Syndrome markers, or having a known infection for which a specimen is being collected. Specimens will be collected at the University of Michigan Health/Sparrow and McLaren Greater Lansing , processed in our lab and stored for analysis at a later date to determine if the microbial pathogens identified by current methods of culture, as well as pathogen susceptibility to antibiotics by culture results, can be identified by the GeneZ technology (no longer in use) or other developed technology accurately, and more timely. It will not affect current patient care nor impact patient care, which will continue in the standard fashion today for sepsis. Results will be compared to standard culture results and antibiotic sensitivities. A secondary aim is related to the antibiotic resistance of the organism causing the infection in an attempt to determine if there are specific characteristics of the organism that allow it to be resistant to certain antibiotics. This requires analysis of the genetic material of the organism in our laboratory. Because there are also human cells in the specimens collected, with separate permission we will evaluate the human genome of the patient with the infection to determine characteristics and conditions that may predict a complicated versus uncomplicated disease course.

Key Dates

Start date

Jun 30, 2015

Status verified

May 2025

Primary completion

Jul 31, 2030

Completion

Jul 31, 2032

Study Design

Enrollment

2,500 participants (estimated)

Arms

• Arm: SIRS positive
  Adult (\> or = 18 years) patients with 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics (1. tachycardia, 2. fever or hypothermia, 3. tachypnea, 4. leukocytosis), who have blood cultures drawn and/or urine collected for the evaluation of suspected sepsis, or those with a source of infection in any other bodily fluid suspected to be the source of infection. (Sputum, stool, saliva, nasal secretions, CSF, wound drainage) May also include others without SIRS criteria but with bodily fluid production or infection of a bodily fluid. With separate permission will analyze human genome and compare characteristics to severity of illness experienced.

Primary Outcome Measure

Correlation of microbial identification with culture results from clinical laboratory [ Time Frame: up to one year per specimen ]

Central Contacts

• Mary J Hughes, DO
  517-353-3211
  [email protected]
• Brett Etchebarne, MD PhD
  517-353-3211
  [email protected]

Locations (2)

Find similar trials in Lansing, MI

Related Studies

• The APS Phenotyping Study
  Recruiting · Vanderbilt University Medical Center · Fresno, California
• A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
  PHASE2 · Recruiting · AstraZeneca · Tucson, Arizona
• Alveolar Dead Space as Predictor of Organ Failure in Severe Sepsis
  Not Yet Recruiting · The University of Texas Health Science Center, Houston · Houston, Texas
• Modulation of Molecular Fingerprinting in Pediatric Sepsis
  Recruiting · Phoenix Children's Hospital · Phoenix, Arizona